ChristopherBrentBentonMD

PubMed

• 1 citations
  Co-management strategies for acute myeloid leukemia patients in the community setting.
  Christopher Benton, Michael R Grunwald, Hana Safah, Margaret Kasner> ;Frontiers in Oncology. 2022 Jan 1
• 3 citations
  Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer.
  Marisa J.L. Aitken, Christopher B. Benton, Ghayas C. Issa, Koji Sasaki, Musa Yilmaz, Nicholas J. Short> ;Acta Haematologica. 2021 Jan 1
• 6 citations
  Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis.
  Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Panagiotis Katsonis, Koji Sasaki, Caleb A. Class, Elias Jabbour, David A. Sallman, Anthony M. Hunter, Christopher B...> ;Blood Cancer Journal. 2021 Mar 6
• 4 citations
  First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations.
  Naval Daver, Allyson Price, Christopher B. Benton, Keyur P. Patel, Weiguo Zhang, Marina Konopleva, Naveen Pemmaraju, Koichi Takahashi, Michael Andreeff, Gautam Borthakur> ;Frontiers in Oncology. 2020 Aug 26
• Thirty-three years later: Two distinct cases of acute lymphoblastic leukemia in one patient.
  Marisa J.L. Aitken, Christopher B. Benton, Feng Wang, Jianhua Zhang, Shelley M. Herbrich, Koichi Takahashi, Carlos E. Bueso-Ramos, Nicholas J. Short> ;American Journal of Hematology. 2020 May 8
• 75 citations
  Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
  Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B. Benton, Caleb A. Class, Kelly S. Chien, Koji Sasaki, Kiran Naqvi, Yesid Alvarado, Tapan M. Kadia, Fa...> ;Blood Advances. 2020 Feb 11
• 85 citations
  Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
  Farhad Ravandi, Rita Assi, Naval Daver, Christopher B. Benton, Tapan M. Kadia, Philip A. Thompson, Gautam Borthakur, Yesid Alvarado, Elias Jabbour, Marina Konopleva, K...> ;The Lancet. Haematology. 2019 Sep 1
• 70 citations
  DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.
  Andrés E. Quesada, Mark J. Routbort, Courtney D. DiNardo, Carlos E. Bueso-Ramos, Rashmi Kanagal-Shamanna, Joseph D. Khoury, Beenu Thakral, Zhuang Zuo, C. Cameron Yin, ...> ;American Journal of Hematology. 2019 May 7
• 19 citations
  Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia
  Christopher B. Benton, Prajwal Boddu, Courtney D. DiNardo, Prithviraj Bose, Feng Wang, Rita Assi, Naveen Pemmaraju, Devendra Kc, Sherry Pierce, Keyur P. Patel, Marina ...> ;Cancer. 2019 Jun 1
• 2 citations
  Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Activ...
  Zhihong Zeng, Wenbin Liu, Christopher B. Benton, Sergej Konoplev, Hongbo Lu, Rui Yu Wang, Julianne Chen, Elizabeth J. Shpall, Keith A. Baggerly, Richard E. Champlin, M...> ;Acta Haematologica. 2019 Jan 1
• 81 citations
  Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
  Nicholas J. Short, Hagop M. Kantarjian, Sanam Loghavi, Xuelin Huang, Wei Qiao, Gautam Borthakur, Tapan M. Kadia, Naval Daver, Maro Ohanian, Courtney D. DiNardo, Zeev E...> ;The Lancet. Haematology. 2019 Jan 1
• 13 citations
  Early detection of transformation to BPDCN in a patient with MDS
  Kamal Chamoun, Sanam Loghavi, Naveen Pemmaraju, Marina Konopleva, Michael H. Kroll, Madeleine Nguyen-Cao, Marisa J Hornbaker, Courtney D. DiNardo, Tapan M. Kadia, Jeff...> ;Experimental Hematology & Oncology. 2018 Oct 6
• 9 citations
  Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
  Benton, C. B., Benton, C. B., Benton, C. B., Benton, C. B., Benton, C. B., Benton, C. B., Chien, K. S., Chien, K. S., Chien, K. S., Chien, K. S., Chien, K. S., Chien, ...> ;Hematological oncology. 2018 Aug 29
• Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
  Kadia, T. M., Kadia, T. M., Cortes, J., Cortes, J., Ravandi, F., Ravandi, F., Jabbour, E., Jabbour, E., Konopleva, M., Konopleva, M., Benton, C. B., Benton, C. B., Bur...> ;The Lancet. Haematology. 2018 Aug 18
• 28 citations
  Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.
  Courtney D. DiNardo, Mark J. Routbort, Sarah A. Bannon, Christopher B. Benton, Koichi Takahashi, Steve Kornblau, Rajyalakshmi Luthra, Rashmi Kanagal-Shamanna, L. Jeffr...> ;Cancer. 2018 Jul 1
• Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R.
  Benton, C. B.,Khan, M.,Sallman, D.,Nazha, A.,Nogueras González, G. M.,Piao, J.,Ning, J.,Aung, F.,Al Ali, N.,Jabbour, E.,Kadia, T. M.,Borthakur, G.,Ravandi, F.,Pierce, ...> ;Am. J. Hematol.. 2018 Jul 28
• 301 citations
  Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
  Courtney D. DiNardo, Caitlin R. Rausch, Christopher B. Benton, Tapan M. Kadia, Nitin Jain, Naveen Pemmaraju, Naval Daver, Wendy Covert, Kayleigh Marx, Morgan Mace, Eli...> ;American Journal of Hematology. 2018 Mar 1
• 16 citations
  Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia
  Prajwal Boddu, Hagop M. Kantarjian, Farhad Ravandi, Guillermo Garcia-Manero, Gautam Borthakur, Michael Andreeff, Elias Jabbour, Christopher B. Benton, Courtney D. DiNa...> ;Leukemia & Lymphoma. 2018 Jan 17
• JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis.
  Paolo Strati, Christopher B. Benton, Taghi Manshouri, Ying Zhang, Joseph E. Bove, Gabriela Sanchez-Petitto, Srdan Verstovsek> ;Leukemia Research. 2017 Dec 1
• 4 citations
  A mind map for managing minimal residual disease in acute myeloid leukemia.
  Christopher B. Benton, Farhad Ravandi> ;Clinical Advances in Hematology & Oncology. 2017 Nov 1
• 31 citations
  Erythroleukemia-historical perspectives and recent advances in diagnosis and management.
  Prajwal Boddu, Christopher B. Benton, Wei Wang, Gautam Borthakur, Joseph D. Khoury, Naveen Pemmaraju> ;Blood Reviews. 2017 Sep 18
• 27 citations
  Targeting Histone Acetylation: Readers and Writers in Leukemia and Cancer.
  Christopher B. Benton, Warren Fiskus, Kapil N. Bhalla> ;Cancer Journal. 2017 Sep 1
• 75 citations
  Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis
  Prajwal Boddu, Hagop M. Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, Srdan Verstovsek, Elias Jabbour, Gautam Borthakur, Marina Konopleva, Kapil N. Bhalla, Nava...> ;Blood Advances. 2017 Jul 25
• 45 citations
  More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia
  Guillermo Montalban-Bravo, Christopher B. Benton, Sa A. Wang, Farhad Ravandi, Tapan M. Kadia, Jorge E. Cortes, Naval Daver, Koichi Takahashi, Courtney D. DiNardo, Elia...> ;Blood. 2017 May 4
• 2 citations
  Increased peripheral leukemia blasts leading to false-positive blood culture
  Maliha Khan, Rabbia Siddiqi, Marina Konopleva, Micah M. Bhatti, Christopher B. Benton> ;Blood Cells, Molecules & Diseases. 2017 May 1
• Join now to see all

Abstracts/Posters

• Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
  Christopher B. Benton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Christopher B. Benton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Christopher B. Benton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
  Christopher B. Benton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia
  Christopher B. Benton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
  Christopher B. Benton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Christopher B. Benton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Bone Marrow Fibrocytes Overexpress Gli1 Oncogenic Transcription Factor in Primary Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Diverse Landscape of TET2 Variants in MDS and AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all